Santa Cruz, California–based Capstan Medical said it’s the first time a minimally invasive robotic structural heart platform has been used in clinical practice.

“Today marks a pivotal moment in the evolution of structural heart therapy,” Capstan Medical CEO Maggie Nixon said in a statement shared with MassDevice ahead of the announcement. “Seeing the capabilities of our system, catheter, and implant come together to deliver groundbreaking human cases validates years of research, development, and unwavering commitment from our team. This achievement demonstrates the potential of our technology to reshape the future of structural heart procedures.”